• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Haemophilus Influenzae Infections - Pipeline Review, H2 2012 Product Image

Haemophilus Influenzae Infections - Pipeline Review, H2 2012

  • ID: 2335264
  • November 2012
  • 78 pages
  • Global Markets Direct

Haemophilus Influenzae Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Haemophilus Influenzae Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Haemophilus Influenzae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Infections. Haemophilus Influenzae Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Haemophilus Influenzae Infections.
- A review READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Haemophilus Influenzae Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Haemophilus Influenzae Infections 9
Haemophilus Influenzae Infections Therapeutics under Development by Companies 11
Haemophilus Influenzae Infections Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Haemophilus Influenzae Infections Therapeutics – Products under Development by Companies 18
Haemophilus Influenzae Infections Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Haemophilus Influenzae Infections Therapeutics Development 20
Sanofi-Aventis 20
GlaxoSmithKline plc 21
Daiichi Sankyo Company, Ltd 22
Merck & Co., Inc. 23
Takeda Pharmaceutical Company Limited 24
Biological E. Limited 25
Wockhardt Limited 26
LG Life Sciences, Ltd 27
Panacea Biotec Limited 28
Sinovac Biotech Ltd. 29
Haemophilus Influenzae Infections – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
Hib Vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GSK2202083A + Prevenar 13 + Rotarix - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
GSK-2189242-A - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Act-HIB reconstituted with TRIPACEL - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Menitorix + Priorix - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
GSK-217744 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DTP-HepB-Polio-Hib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DTP-HepB-Polio-Hib - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
TAK-816 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
DTP-HepB/Hib Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
GSK2189242A + GSK1024850A - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
V-419 + Prevnar 13 + RotaTeq - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 53
NU-300 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Hexaxim - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Easysix - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Group A, C Polysaccharide Meningococcal + Type b Haemophilus Influenzal Conjugate Vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Haemophilus Influenzae Type B Conjugated Vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Second Generation Ketolides - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GSK-2838500A - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
GSK-2838497A - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
GSK-2838501A - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Compound G1 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Haemophilus Influenzae Infections Therapeutics – Drug Profile Updates 65
Haemophilus Influenzae Infections Therapeutics – Discontinued Products 69
Haemophilus Influenzae Infections Therapeutics - Dormant Products 70
Haemophilus Influenzae Infections – Product Development Milestones 71
Featured News & Press Releases 71
Nov 02, 2012: GSK Announces Voluntary Recall Of Infanrix Hexa Due To Potential Contamination 71
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 71
Oct 11, 2012: GSK Announces Voluntary Recall Of Six Batches Of Infanrix Hexa In Australia 71
Jun 22, 2012: Sanofi Pasteur’s Hexaxim Receives Positive Opinion From European Medicines Agency 72
Dec 19, 2011: Viscogel Announces Publication Of Preclinical Results Of ViscoGel 73
Jun 15, 2011: Takeda To Initiate TAK-816 Phase III Clinical Trial In Japan 74
Jul 30, 2010: Sanofi Pasteur to acquire all shares of Joint Venture with Daiichi-Sankyo in Japan 74
Nov 10, 2008: Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine 75
Sep 27, 1996: FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine 75
Jun 24, 1996: Connaught applies to FDA for licensing of first acellular pertussis vaccine to be used in combination with hib vaccine for infants 75
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78

List of Tables
Number of Products Under Development for Haemophilus Influenzae Infections, H2 2012 9
Products under Development for Haemophilus Influenzae Infections – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Sanofi-Aventis, H2 2012 20
GlaxoSmithKline plc, H2 2012 21
Daiichi Sankyo Company, Ltd, H2 2012 22
Merck & Co., Inc., H2 2012 23
Takeda Pharmaceutical Company Limited, H2 2012 24
Biological E. Limited, H2 2012 25
Wockhardt Limited, H2 2012 26
LG Life Sciences, Ltd, H2 2012 27
Panacea Biotec Limited, H2 2012 28
Sinovac Biotech Ltd., H2 2012 29
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 35
Haemophilus Influenzae Infections Therapeutics – Drug Profile Updates 65
Haemophilus Influenzae Infections Therapeutics – Discontinued Products 69
Haemophilus Influenzae Infections Therapeutics – Dormant Products 70

List of Figures
Number of Products under Development for Haemophilus Influenzae Infections, H2 2012 9
Products under Development for Haemophilus Influenzae Infections – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 30
Assessment by Combination Products, H2 2012 31
Assessment by Route of Administration, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 33
Assessment by Molecule Type, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 35

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos